Supplementary Figure S2 from Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma
crossref(2023)
摘要
Supplementary Figure S2: Body weight of HepG2 xenograft-bearing mice treated with iRGD, control (Ctl.) peptide, PBS and doxorubicin.
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要